McKesson Aktie News

McKesson (MCK) wird mit buy bewertet und bietet Kapitalwachstum und Dividendenpotenzial, gestützt auf robustes Umsatz- und EPS-Wachstum. MCKs diversifiziertes Portfolio, Rolle in der Onkologie und Zusammenarbeit mit großen Pharmaunternehmen wie AbbVie sowie das Investment-Grade-Rating von Fitch untermauern das Investment-Argument trotz negativem Eigenkapital. Die Bewertung erscheint attraktiv: ...

This is my latest article, where I provide predictions of upcoming dividend increases from companies with long-term dividend growth histories. With the release of the Federal Reserve stress test results, eight financial institutions announced dividend increases in June. Bank of America is poised to announce its 13th consecutive year of dividend growth in July along with 15 other companies.

These stocks can hold their ground, or even gain, when the market falls. And a garden variety correction—a 10% drop or more—is quite possible.

We believe McKesson's current share price does not adequately reflect the longer-term cash flow generation potential of the business. We believe the current share price of Palantir does not reflect the long-term earnings power of the company. As part of effort to reduce our application software exposure, we concluded our conviction in Tyler's business model advantage and market potential were b...

IRVING, Texas--(BUSINESS WIRE)--McKesson Corporation (NYSE: MCK) announced today the successful completion of the previously announced minority ownership interest investment from funds managed by affiliates of Apollo (“Apollo Funds”) in McKesson's Medical-Surgical Solutions (“MMS”) business on June 1, 2026. This transaction represents a key milestone in McKesson's intention to separate MMS into...

During the quarter, we added 9 new positions and exited 11 positions, bringing the number of positions in the Fund to 41. We reacquired shares of Natera, Inc., a diagnostics company that provides testing services in the oncology, prenatal, and organ transplant settings. We added to the Fund's investment in BillionToOne, Inc., a diagnostics company that is disrupting the market with more accurat...

McKesson Corporation (MCK) Presents at Bank of America Global Healthcare Conference 2026 Transcript

McKesson NYSE: MCK reported a stronger fiscal fourth quarter and full fiscal 2026 performance, with executives pointing to growth across its oncology, multispecialty, pharmaceutical distribution and prescription technology businesses, while outlining plans for continued earnings growth in fiscal 2027.